Condition
Follicular Lymphoma, Grade 2
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 2 (3)
Trial Status
Terminated2
Completed1
Enrolling By Invitation1
Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07545603Phase 2Recruiting
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
NCT03919175Phase 2Terminated
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
NCT07173790Enrolling By Invitation
Watch and Wait or Worry and Wait in Indolent Lymphoma
NCT02966730Early Phase 1Terminated
Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
NCT02710643Phase 2Completed
"MIRO" Molecularly Oriented Immuno-radio-therapy
Showing all 5 trials